Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population
NCT04464512 · West Virginia University · PHASE4 · withdrawn · last registry update 2022-12-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No qualified enrollments; study cancelled due to pandemic” | – | Registry record, West Virginia University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against OPRM1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-12Results posted on the registry: Ochsner Health System, a drug against OPRM1 (NCT03889418)
- 2023-10-18Phase 3 first posted: University of Maryland, Baltimore, Naloxone Nasal Spray (NCT06089707)
- 2023-10-02Results posted on the registry: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, ketamine infusion + Methadone PCA (NCT01594047)
- 2023-09-13Phase 3 first posted: Rutgers, The State University of New Jersey, a drug against OPRM1 (NCT06033599)
- 2023-09-05Phase 3 first posted: Yih-Ing Hser, Injectable extended-release buprenorphine + Sublingual buprenorphine-naloxone (NCT06023459)
- 2023-06-22Phase 3 first posted: Chinese University of Hong Kong, Methadone + Morphine (NCT05913284)
- 2023-04-24Phase 3 first posted: Yale University, Naltrexone Pill + Naltrexone Injection (NCT05827159)
- 2023-03-30Phase 3 first posted: Washington University School of Medicine, Buprenorphine Transdermal Matrix Patch (NCT05790252)
- 2023-03-13Phase 3 first posted: Friends Research Institute, Inc., Methadone Treatment-As-Usual (NCT05766631)
- 2022-10-21Phase 3 first posted: Rutgers, The State University of New Jersey, High Dose Buprenorphine + Standard Buprenorphine Dose (NCT05589181)
- 2022-09-10Results posted on the registry: Karen Derefinko, PhD, a drug against OPRM1 (NCT04464421)
- 2022-07-15Phase 3 first posted: University of Maryland, Baltimore, Methadone (100% dose) + Methadone (50% dose) (NCT05459402)
- 2022-07-14Phase 3 first posted: Baylor College of Medicine, Lemborexant 10 mg + Naltrexone (NCT05458609)
- 2022-06-14Phase 3 first posted: Memorial Sloan Kettering Cancer Center, Methadone (NCT05417100)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision